Clinicians offering early access to Grail’s multi-cancer early detection (MCED) test are waiting for a full NHS trial readout after an endpoint miss, according to reporting. The situation is framed as a debate over whether available trial limitations meaningfully constrain broader implementation ahead of an FDA regulatory decision. For the sector, the controversy centers on how evidence from population-scale screening trials should be interpreted when primary results do not meet expectations. It also reflects the operational question of whether real-world uptake should proceed before regulatory clarity. The next milestones—complete data release, regulatory action, and additional performance analyses—will likely shape payor posture and guideline discussions for MCED programs.